All In Biotech

Drug Trial Radar · NCT06266091

Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

A Phase II, Randomized, Open-label, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of M701 Combined With Systemic Therapy in Patients With Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer.

Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 115 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

115

Actual

Start

Nov 24, 2021

Primary completion

Feb 14, 2024

Study completion Aug 1, 2024

Sponsor

Lead sponsor
Wuhan YZY Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase II, Randomized, Open-label, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of M701 in treating Patients with Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer combined with Systemic Therapy.

Conditions

  • Malignant Ascites

Interventions

  • M701Drug

    Intra-peritoneal infusion of M701 combined with system therapy

  • paracentesisDrug

    paracentesis combined with system therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Puncture-free survival, PuFSTime frame: From the time of 4th dosing (Day 18) to the next puncture/drainage or death (up to 6 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Medical Center of Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.